{"id":"lispro-mix-50-50","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":{"chemblId":"CHEMBL3659218","moleculeType":"Small molecule","molecularWeight":"435.29"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This product contains 50% insulin lispro (a rapid-acting insulin analog) and 50% insulin lispro protamine suspension (an intermediate-acting form). The rapid-acting component begins working within 15 minutes to control postprandial glucose spikes, while the intermediate-acting component provides basal glucose coverage over several hours, mimicking the body's natural biphasic insulin secretion pattern.","oneSentence":"Lispro Mix 50/50 is a combination insulin that provides both rapid-acting and intermediate-acting insulin to control blood glucose in diabetes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:52:33.902Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT01613807","phase":"PHASE4","title":"Humalog® Mix50/50(tm) as a Treatment for Gestational Diabetes","status":"COMPLETED","sponsor":"Sansum Diabetes Research Institute","startDate":"2008-10","conditions":"Gestational Diabetes Mellitus","enrollment":40},{"nctId":"NCT02212951","phase":"PHASE1, PHASE2","title":"Comparison of Postprandial Glucose Control Associated With BIOD-531 vs. Humalog Mix 75/25 vs. Humulin R U-500","status":"COMPLETED","sponsor":"Biodel","startDate":"2014-05","conditions":"Type 2 Diabetes Mellitus","enrollment":12},{"nctId":"NCT01000922","phase":"PHASE2","title":"A Study Comparing the Pharmacodynamic Properties of Insulin VIAJECT™, Regular Human Insulin, and Insulin Lispro","status":"COMPLETED","sponsor":"Biodel","startDate":"2006-06","conditions":"Diabetes Mellitus","enrollment":24},{"nctId":"NCT01175811","phase":"PHASE4","title":"A Study Comparing Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-02","conditions":"Diabetes Mellitus, Type 2","enrollment":402},{"nctId":"NCT01147627","phase":"NA","title":"Effect of Different Interventions on Glycemic Control and β-cell Function in Newly Diagnosed Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2010-08","conditions":"Diabetes Mellitus, Type 2, Newly Diagnosed","enrollment":416},{"nctId":"NCT01398670","phase":"PHASE3","title":"Immunogenicity Study of Wockhardt's Insulin Lispro/Lispro Mix Basal Bolus Regimen in Type 1 Diabetics","status":"WITHDRAWN","sponsor":"Wockhardt","startDate":"2012-02","conditions":"Type I Diabetes","enrollment":""},{"nctId":"NCT01400789","phase":"PHASE1","title":"Comparative Bioequivalence Study of Wockhardt's Insulin Analogue Listro Mix 50/50® and Humalog Mix50/50® in Healthy Subjects","status":"WITHDRAWN","sponsor":"Wockhardt","startDate":"","conditions":"Bioequivalence in Healthy Subjects","enrollment":""},{"nctId":"NCT00971997","phase":"PHASE4","title":"A Study of Insulin Lispro Mix in Type 2 Diabetic Asian Patients","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-09","conditions":"Diabetes Mellitus, Type 2","enrollment":135},{"nctId":"NCT01303042","phase":"NA","title":"Efficacy of Insulin Lispro Mix 50/50 Therapy","status":"UNKNOWN","sponsor":"Aichi Gakuin University","startDate":"2011-02","conditions":"Diabetes Mellitus, Type 2","enrollment":80},{"nctId":"NCT00279201","phase":"PHASE4","title":"The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2005-12","conditions":"Diabetes Mellitus, Type 2","enrollment":2091},{"nctId":"NCT00191581","phase":"PHASE3","title":"Local Registration Trial in China Humalog Mix 50","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2005-03","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["LY275585","Humalog Mix50"],"phase":"marketed","status":"active","brandName":"Lispro Mix 50/50","genericName":"Lispro Mix 50/50","companyName":"Eli Lilly and Company","companyId":"eli-lilly","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lispro Mix 50/50 is a medication used to treat diabetes mellitus, specifically type 1 and type 2, as well as gestational diabetes mellitus. It is a mixed formulation of insulin lispro, a rapid-acting insulin analog.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}